Healthcare Industry News: Bristol-Myers Squibb
News Release - March 8, 2012
S1 Pharmaceuticals Announces New Executive Management and Scientific Advisory Board AppointmentsEmerging Women's Sexual Health BioPharma Strengthens Position in Marketplace with New Additions
JERSEY CITY, N.J., March 8, 2012 -- (Healthcare Sales & Marketing Network) -- S1 Pharmaceuticals, Inc., a developer of therapeutics for disorders of women's sexual health, announced today an executive management addition and Scientific Advisory Board appointment to strengthen and expand the Company's leadership, as follows:
Robert E. Pyke, MD, PhD, a member of the S1 Advisory Board of Directors since October 2011 was appointed as the Company's Chief Medical Officer.
Molly A. Katz, MD was appointed as a member of the Company's Scientific Advisory Board of Directors.
"We are very pleased to welcome Robert to our team, as he will leverage his considerable drug development experience in leading our HSDD and FSD programs," said Nicolas G. Sitchon, CEO of S1. "His clinical experience with disorders of women's sexual health and background in psychiatry will be instrumental to us as we advance Lorexys to Phase I completion in HSDD and beyond."
Dr. Pyke has served as the Company's Scientific Advisory Board Member since October 2011. Prior to S1 he was Director of Clinical Research at Boehringer Ingelheim Pharmaceuticals, where he led the Flibanserin worldwide premenopausal Hypoactive Sexual Desire Disorder (HSDD) clinical program that ended in October 2010. In addition to over fifty publications on Female Sexual Dysfunction (FSD), Dr. Pyke has a distinguished career of leading drug after drug to FDA approval with Parke-Davis, Bristol-Myers Squibb, and Upjohn. Dr. Pyke will lead S1's clinical research with primary focus on the execution and completion of its Phase I clinical trials of Lorexys (S1P-104) in the treatment of HSDD. He has continued his clinical practice treating anxiety, depression, and substance abuse. Dr. Pyke is a member of numerous societies, including the International Society for the Study of Women's Sexual Health. He completed his Ph.D. at the University of Wisconsin, Madison, obtained his M.D. at the University of Miami, and completed his medical training in Internal Medicine at the University of Michigan.
"During my time as a Scientific Advisory Board Member, I was offered a clear view into the tremendous promise of S1 Pharmaceuticals, and I am pleased to take my relationship with the company to the next level as Chief Medical Officer," said Pyke.
Dr. Katz is a board-certified obstetrician-gynecologist practicing in Cincinnati. She has been a lead investigator and author of numerous large, late-phase trials of treatments for HSDD in women. Dr. Katz is a member and past president of the Ohio State Medical Association, an Ohio Delegate to the American Medical Association, and a Fellow of the American College of Obstetrics/Gynecology. She is also active in community affairs and serves as a Board member of the Greater Cincinnati Foundation and as President of The Academy of Medicine of Cincinnati Project Access, a charitable medical services nonprofit for uninsured patients in the community. Dr. Katz obtained her M.D. from the University of Toledo (OH) College Of Medicine and completed her residency in Obstetrics/Gynecology at Emory University in Atlanta.
"As a company focused on women's sexual health, we feel particularly fortunate to have one of the foremost experts in the field, Dr. Molly Katz, joining our scientific advisory board," said Sitchon. "Her contributions will be invaluable as the company approaches its next stage."
About S1 Pharmaceuticals, Inc.
S1 is an early-stage biopharmaceutical company developing therapeutic solutions for disorders of Women's Sexual Health. The most common type of Female Sexual Dysfunction (FSD) is a distressing loss of libido (lack of sexual interest) known as Hypoactive Sexual Desire Disorder (HSDD). S1 is developing its lead product, Lorexys, as an oral drug and will seek to demonstrate that Lorexys can be the first safe and effective treatment approved by the FDA for HSDD in women.
Source: S1 Pharmaceuticals
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.